Kirin has been granted a patent for a method that enables efficient structural analysis of difficult-to-analyze proteins. The patent includes an anti-BRIL antibody and its antigen-binding fragment, as well as the nucleic acid encoding them, a vector containing the nucleic acid, and a method of producing and using the antibody in protein structural analysis. The antibody contains specific amino acid sequences that allow it to bind to BRIL. GlobalData’s report on Kirin gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Kirin, Lactobacilli-based drug compositions was a key innovation area identified from patents. Kirin's grant share as of September 2023 was 27%. Grant share is based on the ratio of number of grants to total number of patents.
Method of stabilizing and analyzing target proteins using antibodies
A recently granted patent (Publication Number: US11773161B2) discloses an anti-BRIL antibody or an antigen-binding fragment thereof. The antibody comprises VH CDRs 1 to 3, which have specific amino acid sequences represented by SEQ ID NOs: 1 to 3, and VL CDRs 1 to 3, which have specific amino acid sequences represented by SEQ ID NOs: 4 to 6.
The patent also covers antigen-binding fragments of the anti-BRIL antibody. These fragments can be selected from a group that includes Fab, Fab', F(ab'), scFv, diabody, dsFv, and a peptide containing multiple CDRs.
This patent provides valuable protection for the disclosed anti-BRIL antibody and its antigen-binding fragments. The specific amino acid sequences of the VH CDRs and VL CDRs are defined, ensuring the uniqueness of the antibody. Additionally, the inclusion of various antigen-binding fragments expands the potential applications of the antibody.
The disclosed antibody and its fragments have potential applications in various fields, including biotechnology, medicine, and research. The antibody's ability to bind to BRIL, a specific target, can be utilized for diagnostic purposes, therapeutic interventions, or as a research tool. The antigen-binding fragments offer flexibility in terms of their size and structure, allowing for different applications based on specific needs.
Overall, this patent represents a significant development in the field of antibody technology. The disclosed anti-BRIL antibody and its antigen-binding fragments provide a novel approach for targeting BRIL and have the potential to contribute to advancements in various industries.
To know more about GlobalData’s detailed insights on Kirin, buy the report here.